Meeting
2020 Genitourinary Cancers Symposium
A prospective study evaluating oral-only hormonal therapy with radiation for intermediate or high-risk prostate cancer in men age ≥ 70 years or with moderate comorbidity.
Authors
Benjamin Ernst Onderdonk
University of Chicago, Chicago, IL
Benjamin Ernst Onderdonk , Paige L. Dorn , Fauzia Arif , Daniel William Golden , Theodore Karrison , Sean P. Pitroda , Russell Zelig Szmulewitz , Stanley L. Liauw
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Clinical Trial Registration Number
NCT01342367
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 303)
Abstract #
303
Poster Bd #
L9
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Phase II randomized study of abiraterone acetate plus ADT versus apalutamide versus abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels. (LACOG 0415).
First Author: Fernando C. Maluf
Poster
2017 Genitourinary Cancers Symposium
A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa).
First Author: Deepak Kilari
Poster
2015 Genitourinary Cancers Symposium
Phase I trial of weekly cabazitaxel with concurrent intensity-modulated radiation therapy (IMRT) and androgen deprivation therapy (ADT) for the treatment of high-risk prostate cancer (PCa).
First Author: Jianqing Lin
Poster
2024 ASCO Genitourinary Cancers Symposium
Weight variation during androgen deprivation therapy in patients with localized prostate cancer: Data from two prospective randomized trials.
First Author: Abdenour Nabid